Advertisement

General Dynamics receives Aegis contract from U.S. Navy

The $40.8 million contract modification is for production of the MK 82/MK 200 Missile Fire Control System director controller equipment.

By Stephen Carlson
The Aegis Weapon System is an air defense missile system that uses the sophisticated SPY-1 radar to track and engage enemy aircraft and missile targets. U.S. Missile Defense Agency photo
The Aegis Weapon System is an air defense missile system that uses the sophisticated SPY-1 radar to track and engage enemy aircraft and missile targets. U.S. Missile Defense Agency photo

May 24 (UPI) -- General Dynamics Ordnance and Tactical Systems has received a $40.8 million modification to an existing contract for production of the MK 82/MK 200 Missile Fire Control System director controller equipment.

The program will deliver fully functional systems with testing and engineering support. It is expected to not affect current ship deployment or operational use. The system is part of the MK99 framework, which is a key element the Aegis Weapon System.

Advertisement

The contract covers systems slated to be delivered to the Republic of Korea and Japan under the Foreign Military Sales Program. The work will be conducted in Saco, Maine, and is expected to be completed by December 2021. Foreign Military Sales funds totaling $40.8 million will be allocated upon award and will not expire at the end of the fiscal year.

The Aegis Weapon System is an air defense missile system that uses the sophisticated SPY-1 radar to track and engage enemy aircraft and missile targets. It is one of the primary weapon systems on U.S. Arleigh Burke-class destroyers and Ticonderoga-class cruisers.

Over 140 sets of the equipment have been delivered, and they are in use on 108 ships. This includes the Republic of Korea's Sejong the Great-class destroyers and Japanese Kongo-class destroyers. Both classes are being outfitted with Ballistic Missile Defense capabilities.

Advertisement

.

Latest Headlines

Advertisement
Advertisement

Follow Us

Advertisement